Open-label, single-arm phase Ib/II study of immune combination therapy with elotuzumab and belantamab mafodotin in patients with relapsed refractory multiple myeloma

被引：0
|
作者：
Browning, Sabrina
Li, Fangyong
Parker, Terri L.
Bar, Noffar
Anderson, Tara
Stevens, Erica
VanOudenhove, Jennifer
Matthews, Martin
Gorshein, Elan
Talsania, Ashita D.
Sabbath, Kert D.
Seropian, Stuart
Halene, Stephanie
Neparidze, Natalia
机构：
[1] Yale Sch Med, Div Hematol, Dept Internal Med, New Haven, CT USA
[2] Yale Sch Publ Hlth, New Haven, CT USA
[3] Yale New Haven Hosp, New Haven, CT USA
[4] Yale Univ, Div Hematol, New Haven, CT USA
[5] Yale Canc Ctr, Div Hematol, New Haven, CT USA
[6] Yale Univ, Div Hematol, Shool Med, New Haven, CT USA
[7] Yale Univ, New Haven, CT USA
[8] Yale Univ, Yale Canc Ctr, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7559
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Everolimus (EVE) for relapsed/refractory classical Hodgkin lymphoma (cHL): Open-label, single-arm, phase II study.
    Johnston, Patrick B.
    Pinter-Brown, Lauren C.
    Rogerio, Jaqueline Willemann
    Warsi, Ghulam
    Chau, Quincy
    Ramchandren, Rod
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma
    Jagannath, Sundar
    Vij, Ravi
    Stewart, A. Keith
    Trudel, Suzanne
    Jakubowiak, Andrzej J.
    Reiman, Tony
    Somlo, George
    Bahlis, Nizar
    Lonial, Sagar
    Kunkel, Lori A.
    Wong, Alvin
    Orlowski, Robert Z.
    Siegel, David S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (05): : 310 - 318
  • [23] Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma.
    Siegel, David
    Jagannath, Sundar
    Lonial, Sagar
    Dimopoulos, Meletios A.
    Graef, Thorsten
    Pietrangelo, Dina
    Lupinacci, Lisa
    Reiser, David
    Rizvi, Syed
    Anderson, Kenneth C.
    BLOOD, 2009, 114 (22) : 1497 - 1497
  • [24] Phase 2, open-label study of venetoclax in combination with carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
    Bueno, Orlando
    Xu, Tu
    Cordero, Jaclyn
    Morris, Lura
    Ross, Jeremy
    Freise, Kevin
    Munasinghe, Wijith
    Leverson, Joel
    Mudd, Sarah
    Verdugo, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [25] An open-label, single-arm phase II study of everolimus (RAD001) in patients with relapsed/refractory classical Hodgkin lymphoma (HL)
    Johnston, P. B.
    Lewis, L. T.
    Rogerio, J. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [26] Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
    Morschhauser, Franck
    Tilly, Herve
    Chaidos, Aristeidis
    McKay, Pamela
    Phillips, Tycel
    Assouline, Sarit
    Batievi, Connie Lee
    Campbell, Phillip
    Ribrag, Vincent
    Damaj, Gandhi Laurent
    Dickinson, Michael
    Jurczak, Wojciech
    Kazmierczak, Maciej
    Opat, Stephen
    Radford, John
    Schmitt, Anna
    Yang, Jay
    Whalen, Jennifer
    Agarwal, Shefali
    Adib, Deyaa
    Salles, Gilles
    LANCET ONCOLOGY, 2020, 21 (11): : 1433 - 1442
  • [27] A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis
    Fox, E. J.
    Sullivan, H. C.
    Gazda, S. K.
    Mayer, L.
    O'Donnell, L.
    Melia, K.
    Lake, S. L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 (02) : 307 - 311
  • [28] Open-label, single-arm, phase II study of enzastaurin in patients with follicular lymphoma
    Schwartzberg, Lee
    Hermann, Robert
    Flinn, Ian
    Flora, Douglas
    Hsi, Eric D.
    Hamid, Oday
    Shi, Peipei
    Lin, Boris K.
    Myrand, Scott P.
    Nguyen, Tuan S.
    Dreyling, Martin
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (01) : 91 - 97
  • [29] Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study
    You, Liangshun
    Liu, Yi
    Mai, Wenyuan
    Xie, Wanzhuo
    Zhou, De
    Mao, Liping
    Chen, Lili
    Zhou, Xinping
    Ma, Liya
    Zheng, Xiaolong
    Wei, Juying
    Lou, Yinjun
    Ye, Xingnong
    Tong, Hongyan
    Jin, Jie
    Meng, Haitao
    EUROPEAN JOURNAL OF CANCER, 2024, 202
  • [30] ELOQUENT-2: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LENALIDOMIDE/DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M.
    Lonial, S.
    Palumbo, A.
    White, D.
    Grosicki, S.
    Spicka, I.
    Walter-Croneck, A.
    Moreau, P.
    Mateos, M. -V.
    Magen, H.
    Belch, A.
    Reece, D.
    Beksac, M.
    Spencer, A.
    Oakervee, H.
    Taniwaki, M.
    Roellig, C.
    Wu, K. L.
    Singhal, A.
    San Miguel, J.
    Matsumoto, M.
    Katz, J.
    Bleickardt, E.
    Poulart, V.
    Richardson, P.
    HAEMATOLOGICA, 2015, 100 : 173 - 173
12345